Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDROCORTISONE SODIUM PHOSPHATE vs BETAMETHASONE DIPROPIONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Hydrocortisone sodium phosphate is a corticosteroid that binds to the glucocorticoid receptor, leading to regulation of gene transcription. It inhibits phospholipase A2, reducing pro-inflammatory mediators such as prostaglandins and leukotrienes. It also suppresses immune cell migration and cytokine production.
Betamethasone dipropionate is a glucocorticoid receptor agonist that binds to cytosolic glucocorticoid receptors, leading to modulation of gene transcription. It suppresses pro-inflammatory cytokines (e.g., IL-1, IL-2, TNF-α), inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and stabilizes mast cells.
Adrenocortical insufficiency,Congenital adrenal hyperplasia,Non-suppurative thyroiditis,Rheumatic disorders (e.g., rheumatoid arthritis, ankylosing spondylitis),Collagen diseases (e.g., systemic lupus erythematosus),Dermatologic diseases (e.g., pemphigus, severe erythema multiforme),Allergic states (e.g., drug hypersensitivity, urticarial transfusion reactions),Ophthalmic diseases (e.g., allergic conjunctivitis, uveitis),Respiratory diseases (e.g., sarcoidosis, berylliosis),Hematologic disorders (e.g., autoimmune hemolytic anemia, thrombocytopenia),Neoplastic diseases (e.g., palliative management of leukemias and lymphomas),Edematous states (e.g., nephrotic syndrome),Gastrointestinal diseases (e.g., ulcerative colitis, Crohn's disease),Miscellaneous: tuberculous meningitis with appropriate antituberculous therapy, trichinosis with neurologic or myocardial involvement
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., psoriasis, eczema, contact dermatitis),Off-label: Lichen planus, discoid lupus erythematosus, alopecia areata
100-500 mg intravenously or intramuscularly every 2-6 hours as needed for acute conditions; typical dose 100 mg IV/IM every 8 hours.
Apply topically as 0.05% cream, ointment, or lotion to affected area once or twice daily. Maximum: 45 g/week.
Terminal elimination half-life approximately 1.5–2 hours; in adrenal insufficiency, dose interval is 8 hours due to HPA axis suppression considerations.
Terminal elimination half-life: 6-8 hours (parenteral); clinically, duration of adrenal suppression may extend beyond this.
No dose adjustment required in renal impairment; hemodialysis does not significantly remove hydrocortisone.
No dosage adjustment required for topical use. For systemic absorption, caution in severe renal impairment.
There is no FDA black box warning for hydrocortisone sodium phosphate. However, corticosteroids including hydrocortisone are associated with increased risk of infection, masking of infection, and reactivation of latent infections.
First trimester: Corticosteroids are associated with a small increased risk of cleft palate (odds ratio ~1.3-3.4). Second/third trimester: Chronic use may increase risk of preterm delivery, intrauterine growth restriction, and maternal hypertension. High doses may cause fetal adrenal suppression.
Betamethasone dipropionate is a corticosteroid. In the first trimester, limited human data; animal studies show increased risk of cleft palate. In second trimester, associated with intrauterine growth restriction (IUGR) and adrenal suppression. In third trimester, used for fetal lung maturity but may cause transient neonatal adrenal suppression. Overall, benefits may outweigh risks with appropriate monitoring.
Hydrocortisone sodium phosphate is a water-soluble prodrug that is rapidly hydrolyzed to hydrocortisone, providing rapid onset of corticosteroid effects. It is commonly used in acute adrenal insufficiency (Addisonian crisis) for rapid glucocorticoid replacement. Avoid use in patients with systemic fungal infections or known hypersensitivity. Monitor for signs of adrenal suppression if used long-term; taper dose gradually to prevent withdrawal. Because of its mineralocorticoid activity, monitor potassium and sodium levels, especially during prolonged therapy.
Betamethasone dipropionate is a high-potency topical corticosteroid used for inflammatory and pruritic dermatoses. Absorption can be significant when applied to large areas or under occlusion, leading to systemic effects like HPA axis suppression. Avoid use on face, groin, or axillae due to risk of atrophy. Not recommended for diaper dermatitis. Monitor for local infections; antifungal/antibacterial may be needed. Use for short courses (2 weeks) and taper dose. In psoriasis, intermittent dosing can reduce relapse. Betamethasone dipropionate is the 17,21-dipropionate ester, enhancing potency and penetration.
No interactions on record
No interactions on record
Common clinical questions about HYDROCORTISONE SODIUM PHOSPHATE vs BETAMETHASONE DIPROPIONATE, answered by our medical review team.
HYDROCORTISONE SODIUM PHOSPHATE is a Corticosteroid that works by Hydrocortisone sodium phosphate is a corticosteroid that binds to the glucocorticoid receptor, leading to regulation of gene transcription. It inhibits phospholipase A2, reducing pro-inflammatory mediators such as prostaglandins and leukotrienes. It also suppresses immune cell migration and cytokine production.. BETAMETHASONE DIPROPIONATE is a Corticosteroid that works by Betamethasone dipropionate is a glucocorticoid receptor agonist that binds to cytosolic glucocorticoid receptors, leading to modulation of gene transcription. It suppresses pro-inflammatory cytokines (e.g., IL-1, IL-2, TNF-α), inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and stabilizes mast cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDROCORTISONE SODIUM PHOSPHATE and BETAMETHASONE DIPROPIONATE depend on the specific clinical indication. These are both Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDROCORTISONE SODIUM PHOSPHATE is: 100-500 mg intravenously or intramuscularly every 2-6 hours as needed for acute conditions; typical dose 100 mg IV/IM every 8 hours.. The standard adult dose of BETAMETHASONE DIPROPIONATE is: Apply topically as 0.05% cream, ointment, or lotion to affected area once or twice daily. Maximum: 45 g/week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDROCORTISONE SODIUM PHOSPHATE and BETAMETHASONE DIPROPIONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDROCORTISONE SODIUM PHOSPHATE is classified as Category D/X. First trimester: Corticosteroids are associated with a small increased risk of cleft palate (odds ratio ~1.3-3.4). Second/third trimester: Chronic use may increase risk of preterm . BETAMETHASONE DIPROPIONATE is classified as Category D/X. Betamethasone dipropionate is a corticosteroid. In the first trimester, limited human data; animal studies show increased risk of cleft palate. In second trimester, associated with. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Hydrocortisone is primarily metabolized in the liver via reduction, hydroxylation, and conjugation with glucuronic acid and sulfate. Key enzymes include 11β-hydroxysteroid dehydrogenase (11β-HSD), 5α-reductase, and 3α-hydroxysteroid dehydrogenase. A small fraction is metabolized by CYP3A4.
Primarily hepatic via CYP3A4; forms inactive metabolites (e.g., 6β-hydroxybetamethasone).
Renal: primarily as inactive metabolites, <1% unchanged; hepatic metabolism to tetrahydrocortisone and glucuronide conjugates; biliary/fecal excretion negligible.
Renal, ~75% as conjugated metabolites; biliary/fecal, ~25%.
Approximately 90% bound, primarily to corticosteroid-binding globulin (CBG, transcortin) and albumin.
64-84% bound to corticosteroid-binding globulin (CBG) and albumin.
Vd approximately 0.3–0.5 L/kg; reflects distribution into total body water with minimal tissue binding; higher in obese patients.
0.6-0.8 L/kg; reflects moderate tissue distribution.
Oral: 96% (rapidly absorbed); IM: 100% (complete); IV: 100%.
Intra-articular: near 100%; intramuscular: 100%; topical: <1% systemically absorbed through intact skin, up to 36% via inflamed or damaged skin.
In severe hepatic impairment (Child-Pugh C), consider dose reduction by 50% due to reduced clearance.
No dosage adjustment required for topical use. For systemic absorption, consider reduced dose in severe hepatic impairment (Child-Pugh C).
0.5-2 mg/kg/day intravenously or intramuscularly divided every 6-12 hours; for acute conditions, up to 1-2 mg/kg/dose every 4-6 hours.
Apply sparingly; limit to smallest amount for effective treatment. Avoid prolonged use, occlusion, and use on face or intertriginous areas. Safety in children under 2 years not established.
Use lowest effective dose; monitor for electrolyte disturbances, hyperglycemia, and increased susceptibility to infections.
Use with caution due to increased susceptibility to skin thinning. Apply minimally and avoid occlusive dressings. Monitor for systemic effects with prolonged use.
No FDA black box warning.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit high-sodium foods to reduce fluid retention and hypertension. Maintain adequate potassium intake through potassium-rich foods (bananas, oranges, spinach) to counteract hypokalemia. Avoid excessive alcohol consumption as it may increase gastrointestinal irritation.
No clinically significant food interactions have been reported for topical betamethasone dipropionate. Systemic absorption is minimal with proper topical use, so dietary restrictions are not required.
Hydrocortisone enters breast milk with an M/P ratio approximately 0.25. At maternal doses ≤20 mg/day, amount in milk is minimal (<1% of maternal dose) and considered compatible. Higher doses may cause adrenal suppression in infant.
Betamethasone is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.9 based on betamethasone data. For dipropionate, minimal systemic absorption expected. Use with caution, especially with high doses. Consider waiting 3-4 hours after dose to breastfeed.
No standard dose adjustment required. Pregnancy may increase corticosteroid clearance, but empirical dose increase is not recommended. Use lowest effective dose for shortest duration.
No specific dose adjustment is routinely required; however, pharmacokinetic changes (e.g., increased clearance, volume of distribution) may necessitate higher doses in severe conditions. Use lowest effective dose. For fetal lung maturation, standard dosing is recommended (e.g., 12 mg intramuscularly, two doses 24 hours apart).
Take exactly as prescribed; do not stop abruptly without doctor's guidance.,Report any signs of infection (fever, sore throat) or worsening of existing conditions.,Carry a medical alert card stating you are taking a corticosteroid.,Avoid live vaccines while on this medication.,Inform all healthcare providers of your corticosteroid use before any surgery or emergency treatment.
Apply a thin layer to the affected skin areas only; do not use on open wounds or broken skin.,Avoid covering the area with bandages or wraps unless directed, as this increases absorption and risk of side effects.,Do not use on your face, groin, or armpits unless specifically instructed by your doctor, as these areas are more susceptible to side effects.,Wash hands after applying, unless treating hands.,Use the medication exactly as prescribed; do not use more often or for longer than recommended to prevent systemic effects.,Inform your doctor if you develop signs of skin infection (increased redness, swelling, pus) or if your condition does not improve after 2 weeks.,Avoid getting the medication in your eyes or mouth. If contact occurs, rinse thoroughly with water.